Call +1 858 457-8383 Fax +1 858 457-8484

Manumycin A

BVT-0091-M001 1 mg $85.00
BVT-0091-M005 5 mg $295.00
Actions
Select size:

* Required Fields

Amount:
Add to Cart
Call +1 858 457-8383
Fax +1 858 457-8484
Contact Us!

Additional Information

Properties
Formula C31H38N2O7
MW 550.6
CAS 52665-74-4
Source/Host Chemicals Isolated from Streptomyces parvulus.
Purity ≥96% (HPLC)
Appearance Yellow to brown powder.
Solubility Soluble in DMSO or methanol; insoluble in water.
Identity Determined by 1H-NMR.
Origin Manufactured by BioViotica.
InChi Key TWWQHCKLTXDWBD-MVTGTTCWSA-N
Product Type Chemical
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C. After reconstitution protect from light at -20°C.
Documents
MSDS Download Document Download

Product Description

  • Antibiotic.
  • Apoptosis and endoplasmic reticulum stress-mediated cell death inducer.
  • Potent, selective and competitive cell permeable rasfarnesyltransferase inhibitor (IC50 = 30 nM).
  • Does not affect geranylgeranyltransferase (IC50 = 180 µM).
  • Inhibition is competitive with respect to farnesyl pyrophosphate and non-competitive with respect to Ras.
  • Neutral sphingomyelinase inhibitor.
  • Blocks insulin-induced MAP kinase activation in rat cardiac myocytes (19 µM).
  • Targets protein phosphatase 1α (PP1α) and reduces hydrogen peroxide.
  • Corrects aberrant splicing of the muscle chloride channel Clcn1 in myotonic dystrophy type 1 (DM1).
  • Shows potential anti-inflammatory activity.

Product References

  1. Identification of Rasfarnesyltransferase inhibitors by microbial screening: M. Hara et al.; PNAS 90, 2281 (1993)
  2. Inhibitors of Rasfarnesyltransferases: F. Tamanoi; TIBS 18, 349 (1993), (Review)
  3. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic: J.B. Gibbs, et al.; Cell 77, 175 (1994)
  4. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes: Y. Zou et al.; J. Biol. Chem. 271, 33592 (1996)
  5. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells: A. Di Paolo, et al.; Br. J. Cancer 82, 905 (2000)
  6. Manumycin A and its analogues are irreversible inhibitors of neutral sphingomyelinase: C. Arenz, et al.; ChemBioChem 2, 141 (2001)
  7. Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells: M. She, et al.; Leukemia 19, 595 (2005)
  8. Binding of manumycin A inhibits IkappaB kinase beta activity: M. Bernier, et al.; J. Biol. Chem. 281, 2551 (2006)
  9. A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimetics: G. Porcu, et al.; Mol. Cancer 9:197 (2010)
  10. Targeting farnesyl-transferase as a novel therapeutcstrategy for mevalonate kinase defiency: In vitro and in vivo approaches: L. De Leo, et al.; Pharmacol. Res. 61, 506 (2010)
  11. Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice: K. Oana, et al.; Sci. Rep. 3, 2142 (2013)
  12. Manumycin induces apoptosis in prostate cancer cells: J.G. Li, et al., Onco Targets Ther. 7, 771 (2014)
  13. The natural tumorcide Manumycin-A targets protein phosphatase 1α and reduces hydrogen peroxide to induce lymphoma apoptosis. G.B. Carey, et al.; Exp. Cell. Res. 332, 136 (2015)
  14. Manumycin A from a new streptomyces strain induces endoplasmic reticulum stress-mediated cell death through specificity protein 1 signaling in human oral squamous cell carcinoma: C.J. Jae, et al.; Int. J. Oncol. 47, 1954 (2015)
  15. Manumycin A downregulates release of proinflammatory cytokines from TNF alpha stimulated human monocytes: E. Cecrdlova, et al.; Immunol. Lett. 169, 8 (2016)
No reviews for this product yet.